Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Appreciated. Grabbed 200k shares today
Whats up with the price being kept around.50
I agree. Good news out today! I see $1-$2 coming soon.
YES! I certainly hope so; I'm so glad I loaded. Never gave up hope. Good company, just been beaten down here lately.
Looking good, hopefully we start going the right direction from here
.60 is where I’m holding — hoping we get start moving
That’s no good — I do not
...anyone know the real reason for the halt on teh CSE...?
Yeah hard to watch but gotta sit tight.
Would really like this sideways show to move up
Could be to cause alerts or maybe MM signals.
What’s the cause of this shit? To cause alerts?
Yeah, no sure wtf that is but OK.
Happened a few more times since
$SHRMF Champignon Brands' Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression
Press Release | 01/25/2021
Champignon Brands' Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression
Canada NewsWire
VANCOUVER, BC, Jan. 25, 2021
Third CRTCE Clinic effectively addresses the unmet need of depression and suicide
VANCOUVER, BC, Jan. 25, 2021 /CNW/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.
Champignon Brands Inc. Logo (CNW Group/Champignon Brands Inc.)
"Over twenty clinical trials have demonstrated that ketamine and esketamine have rapid and robust antidepressant effects in patients that have failed to respond to conventional antidepressants. During the COVID-19 pandemic, the need for effective treatment has become exponentially critical," said Dr. Joshua Rosenblat, Medical Director, CRTCE. "Ketamine treatment for depression is very difficult to access in Canada. This third clinic should allow more people to access treatment."
The first of its kind in Canada, the CRTCE multidisciplinary outpatient clinical research facility has specialized in providing breakthrough rapid onset treatments for depression, including but not limited to intravenous ketamine and intranasal esketamine. These therapies aid patients suffering from several treatment-resistant conditions such as major depressive disorder and/or bipolar disorder.
"In just 30 months through the two current CRTCE Clinics we have administered more than 2500 Intravenous Ketamine Infusions and over 60 Intranasal Ketamine treatments. Many of these patients have experienced substantial relief for what often can be debilitating depression and suicidal thinking," said Kevin Kratiuk, Vice President of Operations, CRTCE.
To obtain treatment, patients must be referred to one of the CRTCE Clinics by family physicians, psychiatrists, or nurse practitioners. Patients with PTSD and OCD are considered on a case-by-case basis. Kratiuk continued, "This newest clinic will expand our capacity to help more people affected by depression".
The new Ottawa clinic is in Ottawa's Alta Vista neighbourhood. "The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression. In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people's lives affected by these common and debilitating disorders in Canada," said Dr. Roger McIntyre, CEO Champignon Brands Inc., Professor of Psychiatry and Pharmacology University of Toronto.
Background
Founded in July 2018, Canadian Rapid Treatment Center of Excellence (CRTCE) (https://www.crtce.com/) is an all-Canadian company. It operates clinics in Mississauga and Toronto and now in Ottawa.
CRTCE provides a platform for treatment development identification of and implementation breakthrough derivatives of ketamine and psychedelics, and innovative delivery platforms for the purpose of treating medical disorders like depression, post-traumatic stress disorder (PTSD) as well as substance and alcohol use disorder.
The CRTCE Clinics offer Intravenous Ketamine Infusion Therapy, Intranasal EsKetamine Therapy and Sublingual/Oral Ketamine Therapy – all aimed at aiding those suffering from several treatment-resistant conditions. The clinic provides a comfortable environment focused on the safety and success of each individual patient.
Champignon Brands Inc. (https://champignonbrands.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. ("AltMed"). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
ON BEHALF OF THE BOARD
"Dr. Roger S. McIntyre"
Dr. Roger S. McIntyre
Chairman & CEO
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company's limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company's industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/champignon-brands-canadian-rapid-treatment-center-of-excellence-opens-first-community-based-centre-in-ottawa-to-provide-ketamine-treatment-for-adults-with-depression-301213532.html
SOURCE Champignon Brands Inc.
Very strange. Never seen anything like that before
maybe, but it popped twice in 4 minutes. Not sure what would cause that.
I saw it also. Glitch?
What just happened with that pop to 1.20?
$SHRMF Champignon Brands Announces New CFO and New General Counsel
Press Release | 01/11/2021
Champignon Brands Announces New CFO and New General Counsel
PR Newswire
VANCOUVER, BC, Jan. 11, 2021
Appointments Complete New Top Management Team Under
Leadership of Chairman and CEO Dr. Roger McIntyre
VANCOUVER, BC, Jan. 11, 2021 /PRNewswire/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the Company's appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm's new General Counsel.
Champignon Brands Inc. Logo (CNW Group/Champignon Brands Inc.)
These appointments complete the Company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors. Dr. McIntyre stated, "these new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response in persons with depression."
Interim CFO Chris Hobbs, named to that position on December 8, 2020, pending the recruitment of a new CFO, remains with the Company as special adviser to Mr. Brooks concerning the British Columbia Securities Commission (BCSC) continuous disclosure review and cease trade order (CTO).
Dr. McIntyre applauded Mr. Hobbs "leadership, competence and professionalism" in taking over these duties on an interim basis in a complete and cooperative response to the BCSC process.
The Company's growth strategy is international in scope and is proceeding even while the Company works with the BCSC toward conclusion of the continuous disclosure review, the lifting of the CTO and the resumption of trading of the Company's securities on the Canadian Securities Exchange.
Dr. McIntyre said Champignon's depression clinic network continues to emerge with current and imminent openings of treatment centres in Toronto, Ottawa, and Montreal. The expansion of the network will continue through Champignon's Canadian Rapid Treatment Centre of Excellence (CRTCE).
Chief Financial Officer, Stephen R. Brooks
Stephen Brooks is a seasoned finance professional with over 25 years experience across a range of industries including telecommunications, sports, entertainment, media, and retail.
Mr. Brooks was formerly Chief Financial Officer of Sim International, a television and movie service provider, CFO of the Ottawa Senators NHL hockey club and Senior Vice-President, Business Operations, of the Toronto Blue Jays and Rogers Centre.
Prior to this, Mr. Brooks spent several years in senior finance roles with Rogers Communications Inc. and Rogers Media Inc., including having responsibility for US and Canadian public reporting requirements.
General Counsel, Peter Rizakos
Peter Rizakos brings to the position of General Counsel 30 years of experience as a corporate and securities lawyer and as an executive in a variety of roles in both established and early-stage businesses.
Most recently, Mr. Rizakos was President and CEO of a private mining company and General Counsel for Marret Asset Management Inc., a Canadian asset manager. He was also top legal officer for one of Canada's leading investment fund companies.
Peter has extensive experience with both public and private companies, including implementation of growth strategies, capital-raising and asset acquisition, legal and regulatory compliance and on board and governance matters.
Professional Affiliations
Stephen Brooks served 10 years in public practice with Deloitte & Touche, LLP in Vancouver, UK, and New York. He is a Chartered Accountant and Chartered Professional Accountant in Ontario and BC and an alumnus of the University of British Columbia and Harvard Business School.
Peter Rizakos articled and practiced law at Blakes in Toronto. He is a member of the Law Society of Ontario, has an MBA from INSEAD and LLB from Osgoode Hall Law School.
Champignon Brands Inc. (https://champignonbrands.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. ("AltMed"). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
ON BEHALF OF THE BOARD
"Dr. Roger McIntyre"
Dr. Roger McIntyre
Chairman & CEO
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/champignon-brands-announces-new-cfo-and-new-general-counsel-301204721.html
SOURCE Champignon Brands Inc.
$SHRMF Champignon Brands Announces New CFO and New General Counsel
Press Release | 01/11/2021
Champignon Brands Announces New CFO and New General Counsel
PR Newswire
VANCOUVER, BC, Jan. 11, 2021
Appointments Complete New Top Management Team Under
Leadership of Chairman and CEO Dr. Roger McIntyre
VANCOUVER, BC, Jan. 11, 2021 /PRNewswire/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the Company's appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm's new General Counsel.
Champignon Brands Inc. Logo (CNW Group/Champignon Brands Inc.)
These appointments complete the Company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors. Dr. McIntyre stated, "these new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response in persons with depression."
Interim CFO Chris Hobbs, named to that position on December 8, 2020, pending the recruitment of a new CFO, remains with the Company as special adviser to Mr. Brooks concerning the British Columbia Securities Commission (BCSC) continuous disclosure review and cease trade order (CTO).
Dr. McIntyre applauded Mr. Hobbs "leadership, competence and professionalism" in taking over these duties on an interim basis in a complete and cooperative response to the BCSC process.
The Company's growth strategy is international in scope and is proceeding even while the Company works with the BCSC toward conclusion of the continuous disclosure review, the lifting of the CTO and the resumption of trading of the Company's securities on the Canadian Securities Exchange.
Dr. McIntyre said Champignon's depression clinic network continues to emerge with current and imminent openings of treatment centres in Toronto, Ottawa, and Montreal. The expansion of the network will continue through Champignon's Canadian Rapid Treatment Centre of Excellence (CRTCE).
Chief Financial Officer, Stephen R. Brooks
Stephen Brooks is a seasoned finance professional with over 25 years experience across a range of industries including telecommunications, sports, entertainment, media, and retail.
Mr. Brooks was formerly Chief Financial Officer of Sim International, a television and movie service provider, CFO of the Ottawa Senators NHL hockey club and Senior Vice-President, Business Operations, of the Toronto Blue Jays and Rogers Centre.
Prior to this, Mr. Brooks spent several years in senior finance roles with Rogers Communications Inc. and Rogers Media Inc., including having responsibility for US and Canadian public reporting requirements.
General Counsel, Peter Rizakos
Peter Rizakos brings to the position of General Counsel 30 years of experience as a corporate and securities lawyer and as an executive in a variety of roles in both established and early-stage businesses.
Most recently, Mr. Rizakos was President and CEO of a private mining company and General Counsel for Marret Asset Management Inc., a Canadian asset manager. He was also top legal officer for one of Canada's leading investment fund companies.
Peter has extensive experience with both public and private companies, including implementation of growth strategies, capital-raising and asset acquisition, legal and regulatory compliance and on board and governance matters.
Professional Affiliations
Stephen Brooks served 10 years in public practice with Deloitte & Touche, LLP in Vancouver, UK, and New York. He is a Chartered Accountant and Chartered Professional Accountant in Ontario and BC and an alumnus of the University of British Columbia and Harvard Business School.
Peter Rizakos articled and practiced law at Blakes in Toronto. He is a member of the Law Society of Ontario, has an MBA from INSEAD and LLB from Osgoode Hall Law School.
Champignon Brands Inc. (https://champignonbrands.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. ("AltMed"). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
ON BEHALF OF THE BOARD
"Dr. Roger McIntyre"
Dr. Roger McIntyre
Chairman & CEO
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/champignon-brands-announces-new-cfo-and-new-general-counsel-301204721.html
SOURCE Champignon Brands Inc.
$SHRMF Review of Bipolar Disorders Confirms Early Diagnosis and Treatment Can Improve Patient Quality of Life
Press Release | 01/08/2021
Review of Bipolar Disorders Confirms Early Diagnosis and Treatment Can Improve Patient Quality of Life
Canada NewsWire
VANCOUVER, BC, Jan. 8, 2021
VANCOUVER, BC, Jan. 8, 2021 /CNW/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – Bipolar Disorders – is published in one of the world's best-known and most reputable scientific journals in medicine - The Lancet.
Champignon Brands Inc. (CNW Group/Champignon Brands Inc.)
The Article contributes to The Lancet's collection of peer-reviewed Seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies." To review the Article, click here.
Bipolar disorders develop before the age of 25 years in 70% of adults and substantially reduce quality of life and psychosocial functioning across the lifespan. Most individuals with bipolar disorders are predominantly affected by depressive symptoms and episodes. Furthermore, about 1.25% of patients with major depressive disorder per year are subsequently diagnosed with a bipolar disorder.
Like schizophrenia, bipolar disorders decrease life expectancy by approximately 10–20 years. Although people with bipolar disorders are approximately 20–30 times more likely to die by suicide compared with the general population, and indeed approximately 30–50% of adults with bipolar disorders have a lifetime history of suicide attempts, suicide is not the primary reason persons with bipolar disorders lose approximately 10-20 potential years of life.
There exist multiple pharmacological treatments for bipolar disorders that have demonstrated efficacy and been approved by health regulatory agencies such as the US Food and Drug Administration and Health Canada. For example, lithium is a well established antimanic agent that is also capable of attenuating depressive symptoms and reducing suicidal ideation. Anti-suicide effects are not observed with other agents commonly prescribed to adults with bipolar disorders. Other treatments for bipolar depression include cariprazine, lurasidone, quetiapine, and the combination of olanzapine–fluoxetine.
These treatments work best in individuals with fewer episodes and shorter illness durations. That is, patients who are diagnosed and receive effective treatment promptly are more likely to recover than are those requiring care through specialised treatment programmes who have already experienced multiple episodes and years of unstable illness.
Unfortunately, individuals with bipolar disorders are often misdiagnosed and do not receive appropriate evidence-based care in a timely fashion. As the article cites, "Most individuals with bipolar disorders are not accurately diagnosed until approximately 6–10 years after first contact with a primary health-care provider, a specialty health-care provider, or both, despite having clinical characteristics of the illness."
The article concludes, "The availability of so-called rapid-onset treatments (e.g., ketamine) and treatments that could mitigate suicidality is crucial to clinical settings. The next decade will see the testing of mechanistically novel agents for bipolar disorders."
As well as CEO of Champignon Brands, Dr. McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. In addition to his recent publication of this article, Dr. McIntyre has published over 600 peer-reviewed scientific articles on bipolar disorders and depression.
Champignon Brands Inc. (https://champignonbrands.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. ("AltMed"). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/review-of-bipolar-disorders-confirms-early-diagnosis-and-treatment-can-improve-patient-quality-of-life-301203107.html
SOURCE Champignon Brands Inc.
PSYCHEDELIC MEDICINE FOR MENTAL HEALTH CONDITIONS
0.6325
https://champignonbrands.com/
Champignon Brands is among the first movers in the psychedelic medicine field and it completed its IPO earlier this year. It is engaged in the production of novel medications, specifically medicinal mushroom products, which aim to treat a variety of mental health problems. It boasts one of the strongest research teams led by
its Special Advisory Committee, working diligently to provide high-quality data to its production team. Hence, SHRMF stock is among the hottest investments in the burgeoning psychedelics field.
It has been a busy 2020 for the Vancouver-based company. In April, it announced that it would be acquiring clinic operator AltMed Capital Corp, aiming at opening several subspecialty therapeutic clinics across the U.S. Additionally, the deal also provides several intellectual properties in developing novel medicines. Moreover, Champignon is also looking to open clinics for psychedelics, such as ketamine, psilocybin and MDMA throughout the North American continent.
It has six current trials in Phase I and pre-clinical stages collectively and seven patents pursuing ketamine/psilocybin solutions. To better reflect its scientific alignments, it is proposing a name change to Apotheosis Scientific Ltd.
https://investorplace.com/2020/12/3-psychedelic-stocks-to-invest-in-the-future-of-medicine/
One of my fav shroom stocks. Finally getting some legs. Was fun loading those cheaps. Those days might be over
twas a good decision loving my position here $SHRMF shroom boom
Weeeeweeee had awesome day we tripping over her chocolate bars I like to see test 100 today
loaded some today i think this has dollarland potential
If you're watching $SHRMF, you've gotta take a look at $SILO https://alphastocknews.com/silo-pharma-silo-stock-to-climb-on-planned-clinical-trial/4880/
.14's I'm In!!!
This b****t is taking up bandwidth.
Chart looks crappy .14's coming
$SHRMF
Sorry, shouldn't have piggybacked on your comment.
You're telling me this, why?
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
662
|
Created
|
03/02/20
|
Type
|
Free
|
Moderators |
Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.
That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.
Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.
Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.
Canada NewsWire
VANCOUVER, BC, Oct. 29, 2020
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.
The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order.
Continuous Disclosure Review History
On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.
In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.
The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.
Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.
On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").
The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order.
For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time. The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.
Dr. Roger McIntyre
Chief Executive Officer
E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line: +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |